Inspection Record

Apothecary Pharma LLC — FDA 483 Findings

US FDAInspected 2025-05-15Published 2025-06-02 8 findingsAseptic processing and sterility assuranceQuality unit oversightContamination controlRegulatory reporting and change controlDocumentation and records

Inspectors Justine Tomasso · Sarah M Gauna · Xiaohui ShenThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding systems for maintaining any equipment used to contJ.·ol the aseptic conditions.

2Quality unit oversight

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

3Contamination control

Protective apparel is not worn as necessary to protect drug products from contamination.

4Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

5Regulatory reporting and change control

Your outsourcing facility has not submitted a report to FDA identifying a product compounded during the previous six months as required by section 503B(b )(2)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

6Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

7Documentation and records

Batch production and control records do not include in-process and laboratory control results for each batch of drug product produced.

8Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.

About this record

Extracted automatically from the document US FDA published on 2025-06-02. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Apothecary Pharma LLC findings history — including this company's other documents US FDA documents, 2025 Go to Findings search